Trackers› Clinical trials› Freiburg im Breisgau

Clinical trial register · Germany

Clinical Trials in Freiburg im Breisgau, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5062 matching records held by the registry are in this view. Synced 20 Oct 2026, 03:18 UTC

5062

Studies in scope

all four open statuses

2873

Recruiting now

open to new participants

988

Lead sponsors

across recruiting studies

Top sites

Berlin 1586 Hamburg 889 Essen 766 Dresden 716 Heidelberg 627

Trials with a site in Freiburg im Breisgau

Status

Study

Lead sponsor

Phase

Enrol

Sites in Germany

Start

Not yet open

A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

NCT07789015Idiopathic Inflammatory Myopathies

DrugNerandomilast

Boehringer Ingelheim

Phase 3

270

Bad Bramstedt, Berlin, Cologne, Erlangen, Freiburg im Breisgau, Halle, Jena, Kirchheim unter Teck

2026-12-14

Not yet open

Dalbavancin Therapy for Infective Endocarditis

NCT07699211Endocarditis Infective, Endocarditis, Bacterial

DrugDalbavancin administration

Stefan Hagel

Phase 3

184

Freiburg im Breisgau, Regensburg, Hamburg, Cologne, Leipzig, Berlin, Erfurt, Jena

2026-12

Not yet open

A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

NCT07728188Relapsed or Refractory Multiple Myeloma

DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide

AbbVie

Phase 3

520

Freiburg im Breisgau, Karlsruhe, Tübingen, Ulm, Würzburg, Hanover, Bonn, Cologne

2026-11-30

Not yet open

ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

NCT07850063Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease

Boehringer Ingelheim

Phase 3

600

Freiburg im Breisgau, Leipzig, Mainz

2026-10-23

Recruiting

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

NCT07619118Hypercholesterolaemia

DrugsRosuvastatin 1·Rosuvastatin 2

AstraZeneca

Phase 3

200

Berlin, Essen, Frankfurt, Freiburg im Breisgau, Hanover, Kaiserslautern, Leipzig, Munich

2026-09-10

Recruiting

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

NCT07623161Myelofibrosis, Anemia

DrugElritercept

Takeda

Phase 3

324

Freiburg im Breisgau, Heidelberg, Mutlangen, Minden, Koblenz, Chemnitz, Halle, Jena

2026-09-10

Recruiting

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

NCT07623200Essential Thrombocythemia

DrugINCA033989

Incyte Corporation

Phase 3

426

Aachen, Berlin, Dresden, Freiburg im Breisgau, Halle, Hamburg, Hanover, Homburg

2026-09-08

Not yet open

Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial

NCT07788586Candidemia, Invasive Candidiasis

Oliver Cornely, MD

Phase 4

420

Aachen, Berlin, Cologne, Dresden, Düsseldorf, Frankfurt am Main, Freiburg im Breisgau, Giessen

2026-09

Not yet open

Study of Serine Supplementation to Protect Vision in MacTel

NCT07342439Macular Telangiectasia Type 2 (MacTel)

The Lowy Medical Research Institute Limited

Phase 3

120

Bonn, Freiburg im Breisgau, Münster

2026-09

Not yet open

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)

DrugsASCT·AZD0120·Melphalan·Lenalidomide

AstraZeneca

Phase 3

750

Berlin, Dresden, Essen, Freiburg im Breisgau, Hamburg, Leipzig, München, Oldenburg

2026-08-25

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2

DrugLenbelintide

AstraZeneca

Phase 3

1,500

Berlin, Bochum, Bünde, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg

2026-08-20

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

NCT07784725Obesity or Overweight

DrugLenbelintide

AstraZeneca

Phase 3

2,500

Berlin, Bochum, Bünde, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg

2026-08-19

Recruiting

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

NCT07497087Systemic Sclerosis

Boehringer Ingelheim

Phase 3

448

Bad Bramstedt, Berlin, Dresden, Freiburg im Breisgau, Hanover, Heidelberg, Lübeck, Münster

2026-07-27

Recruiting

Registry for Duchenne and Becker Muscular Dystrophy

NCT07402122Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy, Dystrophinopathy Symptomatic Female Carrier

Dr. Andreas Ziegler

Observational

1,500

Berlin, Bochum, Bonn, Bremen, Dresden, Erlangen, Essen, Freiburg im Breisgau

2026-07-13

Recruiting

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)

DrugsObrixtamig·Etoposide·Carboplatin

Boehringer Ingelheim

Phase 3

390

Berlin, Bonn, Cologne, Dresden, Düsseldorf, Erlangen, Freiburg im Breisgau, Hamburg

2026-07-10

Recruiting

A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.

NCT07672236Head & Neck Cancer, Oral Mucositis

OncoZenge AB

Phase 3

150

Cologne, Frankfurt am Main, Freiburg im Breisgau, Kiel, Tübingen

2026-07-07

Recruiting

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

NCT07764978Newly Diagnosed Multiple Myeloma

DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab

AstraZeneca

Phase 3

750

Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Hamburg, Kiel, Leipzig

2026-06-26

Recruiting

Dehydroepiandrosterone (DHEA) as Augmentation of Standard Antidepressants in Treatment-resistant Depression.

NCT07843927Treatment Resistant Depression (TRD)

DrugsDehydroepiandrosterone·DHEA

Charite University, Berlin, Germany

Phase 3

320

Berlin, Augsburg, Frankfurt, Freiburg im Breisgau, Hamburg, Leipzig, München, Stralsund

2026-06-22

Recruiting

Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer

NCT07563595Breast Cancer

DrugElacestrant

iOMEDICO AG

Observational

500

Freiburg im Breisgau, Paderborn, Ravensburg

2026-06-19

Recruiting

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

NCT07647328ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Ribociclib

AstraZeneca

Phase 3

150

Berlin, Düsseldorf, Erlangen, Freiburg im Breisgau, Mönchengladbach, München, Paderborn, Trier

2026-06-15

Recruiting

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

NCT07652658Idiopathic Pulmonary Fibrosis (IPF)

AstraZeneca

Phase 2

359

Bonn, Essen, Freiburg im Breisgau, Fulda, Giessen, Hamburg, Hanover, Heidelberg

2026-06-11

Recruiting

A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)

NCT07559799Multiple Myeloma

iOMEDICO AG

Observational

Freiburg im Breisgau

2026-06-01

Recruiting

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT07518186Multiple Myeloma

DrugsRamantamig·Teclistamab

Janssen Research & Development, LLC

Phase 3

700

Freiburg im Breisgau, Hamburg, Tübingen

2026-05-31

Recruiting

Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.

NCT07627568Acute Myeloid Leukemia

University of Freiburg

Observational

Freiburg im Breisgau

2026-05-30

Recruiting

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT07124078Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 2

Berlin, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Hanover, Regensburg

2026-05-20

Recruiting

Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

NCT07286214Polymyalgia Rheumatica

DrugSarilumab

Sanofi

Phase 4

300

Berlin, Freiburg im Breisgau, Hamburg, Herne, Neubrandenburg, Würzburg

2026-05-12

Recruiting

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

NCT07441694Myeloproliferative Neoplasms

Incyte Corporation

Phase 1

218

Aachen, Berlin, Freiburg im Breisgau, Halle, Mainz

2026-05-11

Recruiting

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

NCT07555483Alpha 1 Antitrypsin Deficiency

Grifols Therapeutics LLC

Phase 3

Freiburg im Breisgau

2026-05-05

Recruiting

A Study to Evaluate the Performance and Safety of Artelac® Complete MDO® Versus VISMED® MULTI Eye Drops in the Management of Moderate to Severe Dry Eye Disease

NCT07593885Dry Eye

Dr. Gerhard Mann chem.-pharm. Fabrik GmbH

Not applicable

160

Freiburg im Breisgau, Heidelberg, Tübingen, Munich, Nuremberg, Prien am Chiemsee, Ahaus, Brühl

2026-04-30

Recruiting

Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC

NCT07242352Breast Cancer, HR+/HER2- Breast Cancer

DrugElacestrant

Women's Cancer Study Group GmbH

Phase 3

1,520

Mannheim, Tübingen, Esslingen am Neckar, Freiburg im Breisgau, Amberg, Augsburg, München, Würzburg

2026-04-29

Recruiting

A Study of Lebrikizumab in Adults With Nummular Eczema

NCT07542483Nummular Eczema

DrugLebrikizumab

Almirall, S.A.

Phase 3

270

Freiburg im Breisgau

2026-04-24

Recruiting

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

NCT07387367Adenovirus Infections

SymBio Pharmaceuticals

Phase 3

180

Berlin, Essen, Frankfurt, Freiburg im Breisgau, Hamburg, Hanover, Münster, Tübingen

2026-03-17

Recruiting

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07287150Metastatic Castration-Resistant Prostate Cancer

DrugsInavolisib·Abiraterone·Enzalutamide·Docetaxel

Hoffmann-La Roche

Phase 2

100

Freiburg im Breisgau, Hamburg, Münster, Nürtingen

2026-03-11

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

NCT07282574Progressive Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 2

360

Freiburg im Breisgau, Mannheim, Tübingen, Ulm, Erlangen, Munich, Frankfurt am Main, Bochum

2026-03-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849CRC (Colorectal Cancer)

DrugsINCA33890·Folfox·Bevacizumab

Incyte Corporation

Phase 3

700

Berlin, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Hanover, Lübeck

2026-03-05

Recruiting

EASY Algorithm Trial (Elbow Trauma Assessment Using Sonography in Children and Youth) Diagnostic Accuracy and Safety of Point-of-care Ultrasound as a Screening Tool for Suspected Elbow Fractures in Children Aged 5 to 15 Years: a Multicenter Prospective Cohort Study

NCT07429344Elbow Fractures, Distal Humerus Fracture, Pediatric Trauma, Radius Fracture

Timo Munz

Observational

543

Amberg, Berlin, Chemnitz, Dresden, Duisburg, Freiburg im Breisgau, Hamburg, Kassel

2026-03-02

Recruiting

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657Relapsed Refractory Multiple Myeloma

DrugsAZD0120·Darzalex·Velcade·Carfilzomib

AstraZeneca

Phase 3

508

Berlin, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Leipzig, Mainz

2026-02-23

Recruiting

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer

DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin

AstraZeneca

Phase 3

2,130

Augsburg, Bad Saarow, Berlin, Bonn, Dresden, Essen, Frankfurt, Freiburg im Breisgau

2026-02-03

Recruiting

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer

DrugsSigvotatug vedotin·PF-08634404

Pfizer

Phase 1/2

162

Freiburg im Breisgau, Frankfurt am Main, Düsseldorf

2026-01-30

Recruiting

Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis

NCT07332091Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis

CSL Behring

Phase 2

Freiburg im Breisgau, Heidelberg, Leipzig, Weinheim

2026-01-22

Not yet open

Incidence of Colon Ischemia in Patients After Cardiopulmonary Resuscitation (CPR)

NCT07359313Cardiac Arrest (CA)

University Hospital Freiburg

Not applicable

200

Freiburg im Breisgau

2026-01-07

Recruiting

A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta

NCT07078383Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic

Vascutek Ltd.

Not applicable

150

Freiburg im Breisgau, Hamburg, Stuttgart

2025-12-19

Recruiting

A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany

NCT07255638Indolent Systemic Mastocytosis

DrugAvapritinib

Blueprint Medicines Corporation

Observational

Berlin, Bochum, Deggendorf, Dresden, Freiburg im Breisgau, Göttingen, Leipzig, Munich

2025-12-09

Recruiting

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab

AstraZeneca

Phase 3

1,100

Aachen, Berlin, Bonn, Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Hamburg

2025-12-04

Recruiting

Early Detection and IntervenTion in Heart Failure

NCT07731490Heart Failure (HF)

University Hospital, Basel, Switzerland

Not applicable

18,000

Freiburg im Breisgau, Herne, Leipzig

2025-12-03

Recruiting

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310Parkinson's Disease

DrugPrasinezumab

Hoffmann-La Roche

Phase 3

900

Beelitz, Berlin, Bochum, Dresden, Düsseldorf, Erlangen, Freiburg im Breisgau, Hanover

2025-11-24

Recruiting

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

1,275

Freiburg im Breisgau, Mannheim, Munich, Unterhaching, Cottbus, Leipzig, Halle, Jena

2025-11-11

Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)

DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin

Boehringer Ingelheim

Phase 3

670

Aachen, Berlin, Berlin-Spandau, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Gauting

2025-11-07

Recruiting

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

NCT07015242Lymphoma

DrugsProcarbazine·Liso-cel·Lisocabtagene maraleucel·Calcium folinate

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 2

Freiburg im Breisgau, Ulm, Cologne, Essen, Chemnitz, Berlin, Göttingen, Hamburg

2025-11-06

Recruiting

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT06888193Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa

DrugBimekizumab

UCB Biopharma SRL

Phase 1

Freiburg im Breisgau, Herne

2025-11-05

Recruiting

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT07007065Neovascular Age-related Macular Degeneration

DrugSurabgene Lomparvovec

AbbVie

Phase 3

561

Freiburg im Breisgau, Tübingen, Ulm, Munich, Göttingen, Hanover, Bonn, Ludwigshafen am Rhein

2025-11-05

Recruiting

Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA

NCT07089576Aortic Arch Aneurysm, Aortic Arch Dissection, Chronic Aortic Dissection, Acute Aortic Dissection

Artivion Inc.

Not applicable

132

Berlin, Freiburg im Breisgau, Leipzig

2025-11-04

Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037Non-small Cell Lung Cancer (NSCLC)

DrugsDato-DXd·Docetaxel

AstraZeneca

Phase 3

400

Bad Saarow, Bielefeld, Bonn, Cologne, Essen, Frankfurt, Freiburg im Breisgau, Gauting

2025-10-31

Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

NCT07173751Breast Neoplasms

DrugsEribulin·Pumitamig·Gemcitabine·Carboplatin

BioNTech SE

Phase 3

558

Augsburg, Bremen, Frankfurt, Freiburg im Breisgau, Gera, Hamburg, Koblenz, Mannheim

2025-10-30

Recruiting

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

NCT07194850Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura

DrugEfgartigimod

argenx

Phase 2/3

Berlin, Freiburg im Breisgau

2025-10-20

Recruiting

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

NCT06997588PIK3CA-related Overgrowth Spectrum (PROS)

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2

140

Freiburg im Breisgau, Düsseldorf, Leipzig, Halle, Berlin, Stuttgart

2025-10-09

Recruiting

Clinical Evaluation of a New Platform for Bi-manual Endoscopic Resection in the Rectum and Sigma (EndoTEM)

NCT07146165Adenoma Colon Polyp, Adenoma Colon

Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)

Not applicable

Freiburg im Breisgau, Ludwigsburg, Stuttgart

2025-10-02

Recruiting

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)

DrugNNC6019-0001

Novo Nordisk A/S

Phase 3

1,280

Bad Oeynhausen, Berlin, Cologne, Dresden, Frankfurt am Main, Freiburg im Breisgau, Jena, Kiel

2025-10-02

Not yet open

Protoporphyrin Imaging in Multispectral Evaluation of Resections

NCT07021573Glioma

Medical University Innsbruck

Not applicable

Berlin, Freiburg im Breisgau, Göttingen, München, Münster, Tübingen

2025-09-30

Recruiting

Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in Advanced Rare Cancers

NCT06855134Rare Cancer

German Cancer Research Center

Observational

946

Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg

2025-09-29

Recruiting

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967Plaque Psoriasis

DrugsUstekinumab·Deucravacitinib

Bristol-Myers Squibb

Phase 3

3,040

Freiburg im Breisgau, Langenau, Mahlow, Hamburg, Bad Bentheim, Münster, Mainz, Quedlinburg

2025-09-22

Recruiting

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07111520Non-small Cell Lung Cancer

DrugsBNT326·Pumitamig

BioNTech SE

Phase 1/2

880

Dresden, Freiburg im Breisgau, Heidelberg

2025-09-22

Active, closed

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07169578Alzheimers Disease

DrugTrontinemab

Hoffmann-La Roche

Phase 3

1,101

Aachen, Bad Homburg, Bayreuth, Bochum, Bremen, Erbach/Odenwald, Freiburg im Breisgau, Hamburg

2025-09-17

Active, closed

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

414

Berlin, Bonn, Braunschweig, Bremen, Cologne, Düsseldorf, Essen, Freiburg im Breisgau

2025-09-13

Recruiting

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

DrugsCasdatifan·Cabozantinib

Arcus Biosciences, Inc.

Phase 3

720

Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Halle, Hanover, Heidelberg

2025-09-08

Recruiting

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

Eli Lilly and Company

Phase 3

10,450

Aachen, Bad Homburg, Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Greifswald

2025-09-02

Not yet open

European Prospective Bloodstream Infection Cohort

NCT07082322Bloodstream Infection

University Hospital Freiburg

Observational

40,000

Freiburg im Breisgau

2025-09-01

Recruiting

SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment

NCT07145190Parkinson Disease

Bial - Portela C S.A.

Observational

Berlin, Bochum, Freiburg im Breisgau, Fulda, Hetzdorf, Osnabrück, Siegen, Sundern

2025-08-27

Recruiting

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer

DrugsCapivasertib·Fulvestrant

Relay Therapeutics, Inc.

Phase 3

540

Aschaffenburg, Bottrop, Dresden, Eggenfelden, Erlangen, Freiburg im Breisgau, Krefeld, Mannheim

2025-08-26

Recruiting

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

NCT07058077Heterozygous Familial Hypercholesterolemia (HeFH)

DrugsEnlicitide·Enlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 2/3

153

Freiburg im Breisgau

2025-08-21

By invitation

Transfemoral TAVI With or Without Coronary Angiogram in Patients With Severe Aortic Stenosis (PURE TAVI)

NCT06898086Severe Aortic Stenosis

Rede Optimus Hospitalar SA

Not applicable

620

Düsseldorf, Essen, Freiburg im Breisgau, Lübeck, Ulm

2025-08-08

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Augsburg, Bielefeld, Dresden, Frankfurt, Freiburg im Breisgau, Hanover, Leipzig, Munich

2025-08-06

Recruiting

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

NCT07075016Acute Myeloid Leukemia

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 3

227

Berlin, Bochum, Bonn, Braunschweig, Bremen, Darmstadt, Flensburg, Freiburg im Breisgau

2025-08-05

Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336Endometrial Cancer, Malignant Solid Tumour

DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel

AstraZeneca

Phase 3

800

Amberg, Chemnitz, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg

2025-08-01

Not yet open

Gastroduodenal Full Thickness Resection Device Registry - gdFTRD® Registry

NCT07142902Subepithelial Gastrointestinal Tumors, Adenoma

Ovesco Endoscopy AG

Observational

306

Freiburg im Breisgau, Ludwigsburg, Stuttgart

2025-08

Not yet open

Telerehabilitation Decision Support System: Pilot Testing Protocol

NCT07079787Stroke, Mild Cognitive Impairment (MCI), Vestibular Disease, Long Covid-19

University College, London

Not applicable

Freiburg im Breisgau

2025-07-25

Recruiting

A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.

NCT06832722Shock, Cardiogenic

4TEEN4 Pharmaceuticals GmbH

Phase 1/2

Berlin, Freiburg im Breisgau, Hamburg, Leipzig, Mannheim

2025-07-13

Recruiting

Treatment Monitoring for NTM Infections With a Symptom Diary

NCT07131774Non-Tuberculous Mycobacterial (NTM) Infections

Research Center Borstel

Observational

200

Freiburg im Breisgau, Frankfurt am Main, Borstel

2025-07-11

Active, closed

Lebrikizumab in Moderate-to-severe Atopic Dermatitis

NCT06906497Atopic Dermatitis

DrugLebrikizumab

Johann E Gudjonsson MD PhD

Phase 4

Freiburg im Breisgau

2025-07-02

Active, closed

Radial Versus Femoral Secondary Access in Patients Undergoing TAVI

NCT07399392TAVI(Transcatheter Aortic Valve Implantation)

University Heart Center Freiburg - Bad Krozingen

Not applicable

600

Freiburg im Breisgau

2025-07-01

Recruiting

Clinical Study on the Safety and Efficacy of the Minimally Invasive Ennovate® Method for Pedicle Screw Placement

NCT06960018Cervical Spine Disease, Pain, Postoperative

Aesculap AG

Not applicable

Aachen, Berlin, Freiburg im Breisgau

2025-06-20

Active, closed

A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease

NCT07048197Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 1/2

Freiburg im Breisgau, Göttingen, Cologne, Berlin, Ulm

2025-06-20

Active, closed

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744Ulcerative Colitis

DrugsRisankizumab·Vedolizumab

AbbVie

Phase 3

573

Freiburg im Breisgau, Ulm, Dachau, Erlangen, Regensburg, Frankfurt am Main, Essen, Minden

2025-06-17

Active, closed

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 3

Aachen, Berlin, Cologne, Dresden, Erlangen, Frankfurt am Main, Freiburg im Breisgau, Göttingen

2025-06-04

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

Augsburg, Cologne, Dresden, Frankfurt, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel

2025-06-04

Active, closed

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

NCT07000123Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

3,103

Amberg, Bad Homburg, Berlin, Dresden, Essen, Falkensee, Frankfurt, Freiburg im Breisgau

2025-05-28

Recruiting

Brain Signal Training to Enhance Affect Down-regulation

NCT06626789Borderline Personality Disorder

Central Institute of Mental Health, Mannheim

Phase 1/2

164

Freiburg im Breisgau, Giessen, Halle, Hamburg, Mannheim, Tübingen

2025-04-23

Active, closed

A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

NCT06928142Sjogren Disease

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2

Freiburg im Breisgau, Cologne, Hamburg, München

2025-04-23

Recruiting

Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

NCT06810609Lung Cancer Non-Small Cell Cancer (NSCLC)

University Hospital, Bonn

Phase 2

176

Freiburg im Breisgau, Stuttgart, Giessen, Minden, Bonn

2025-04-20

Recruiting

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

NCT06846671CLL, Chronic Lymphocytic Leukemia

DrugsIdelalisib·Tacabrutideg·Bendamustine·Venetoclax

BeOne Medicines

Phase 3

250

Augsburg, Berlin, Chemnitz, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg

2025-04-10

Recruiting

Investigation of a New Window Into Intracranial Pressure: Venous Occlusion Pressure of the Isolated Periorbital Vein

NCT07053631Indication for CSF Dynamic Testing, Indication for CSF Infusion Test

University of Freiburg

Not applicable

Freiburg im Breisgau

2025-04-07

Recruiting

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer

DrugsRibociclib·Fulvestrant

Novartis Pharmaceuticals

Phase 1/2

280

Freiburg im Breisgau, Heidelberg, Ulm

2025-04-03

Recruiting

Early TIPS in Patients With Liver Cirrhosis and Ascites

NCT06576934Liver Cirrhosis, Ascites Hepatic, Portal Hypertension

University Hospital Freiburg

Not applicable

134

Freiburg im Breisgau

2025-04-01

Active, closed

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

NCT06863961Atopic Dermatitis

DrugAfimkibart

Hoffmann-La Roche

Phase 2

162

Freiburg im Breisgau, Bad Bentheim, Merzig, Chemnitz, Quedlinburg, Hamburg

2025-04-01

Active, closed

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

565

Freiburg im Breisgau, Würzburg, Frankfurt am Main, Düsseldorf, Merzig, Leipzig, Bad Bentheim, Berlin

2025-03-20

Recruiting

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

NCT06668181Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis

DrugBimekizumab

UCB Biopharma SRL

Phase 3

Berlin, Dresden, Freiburg im Breisgau, Hamburg, Sankt Augustin, Sendenhorst, Tübingen

2025-03-11

Recruiting

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623Non Small Cell Lung Carcinoma, c-MET

DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin

AbbVie

Phase 1/2

252

Freiburg im Breisgau, Heilbronn, Augsburg, Würzburg, Frankfurt am Main, Cologne, Hemer, Oldenburg in Holstein

2025-03-06

Recruiting

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

NCT07558668Moderate to Severe Atopic Dermatitis

Sitryx Therapeutics Ltd

Phase 1

149

Berlin, Frankfurt, Freiburg im Breisgau

2025-02-26

Active, closed

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

NCT06878404Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

552

Bad Bentheim, Berlin, Dresden, Freiburg im Breisgau, Hamburg, Herne, Langenau, Minden

2025-02-21

Recruiting

Fruquintinib in Patients With Metastatic Colorectal Cancer

NCT06787105Metastatic Colorectal Cancer (mCRC)

iOMEDICO AG

Observational

150

Biberach, Freiburg im Breisgau, Heidelberg, Ravensburg, Schorndorf, Weinheim, Aschaffenburg, Fürth

2025-02-17

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

NCT06624670Pyoderma Gangrenosum

DrugsSpesolimab·Prednisolone·Prednisone

LEO Pharma

Phase 3

Berlin, Düsseldorf, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Tübingen, Würzburg

2025-02-05

Recruiting

Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)

NCT06897839Bronchopulmonary Dysplasia

Airway Therapeutics, Inc.

Phase 2/3

366

Dresden, Freiburg im Breisgau, Regensburg

2025-02-03

Recruiting

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

NCT06659549Geographic Atrophy of the Macula

Galimedix Therapeutics Inc

Phase 2

110

Bonn, Freiburg im Breisgau, Hanover, Neubrandenburg, Tübingen, Ulm

2025-01-10

Recruiting

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

NCT06609226Sickle Cell Disease, Thalassemia

Novo Nordisk A/S

Phase 3

480

Berlin, Freiburg im Breisgau

2025-01-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

NCT06807424Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

750

Berlin, Cologne, Dresden, Freiburg im Breisgau, Hamburg, Herne, Langenau, Ratingen

2025-01-09

Recruiting

REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization

NCT06922175Epilepsy With Uncontrolled Focal-onset Seizures

Aziende Chimiche Riunite Angelini Francesco S.p.A

Observational

200

Freiburg im Breisgau, Hamburg, Kork

2024-12-19

Recruiting

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

NCT06423573Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional

Chiesi Farmaceutici S.p.A.

Observational

170

Freiburg im Breisgau

2024-12-18

Active, closed

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsBudigalimab·Telisotuzumab Adizutecan·Fluorouracil·Leucovorin

AbbVie

Phase 2

185

Freiburg im Breisgau, Munich, Frankfurt am Main, Leipzig, Hamburg

2024-12-13

Recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019Familial Hypercholesterolemia - Heterozygous

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

Freiburg im Breisgau, Frankfurt am Main, Hanover

2024-12-09

Active, closed

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

NCT06588686Idiopathic Pulmonary Fibrosis (IPF)

Vicore Pharma AB

Phase 2

378

Freiburg im Breisgau, Heidelberg, Tübingen, Frankfurt am Main, Immenhausen, Hanover, Essen, Berlin

2024-12-09

Recruiting

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

NCT06679140COVID-19 SARS-CoV-2 Infection

DrugIbuzatrelvir

Pfizer

Phase 3

2,330

Munich, Frankfurt am Main, Obertshausen, Cologne, Augsburg, Berlin, Freiburg im Breisgau, Hamburg

2024-12-08

Active, closed

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969Sjogrens Syndrome

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

655

Cologne, Dresden, Erlangen, Freiburg im Breisgau, Hamburg, Hanover, Herne, München

2024-12-04

Recruiting

Genetic Newborn Screening for Rare Diseases Within the Screen4Care Project

NCT06549218Newborn Screening

University Hospital Freiburg

Not applicable

20,000

Berlin, Freiburg im Breisgau, Göttingen

2024-12-03

Recruiting

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325Systemic Lupus Erythematosus

UCB Biopharma SRL

Phase 3

450

Berlin, Cologne, Dessau, Dresden, Freiburg im Breisgau, Greifswald, Herne, Jena

2024-11-21

Recruiting

A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING

NCT06712628Moderate to Severe Rheumatoid Arthritis

AbbVie

Observational

678

Freiburg im Breisgau, Heidelberg, Tübingen, Ulm, Amberg, Augsburg, Bamberg, Erlangen

2024-11-07

Recruiting

The Freiburg Registry on SpontanEous IntercrAnial Hypotension (SIH) & Post-duraL Puncture Headache (PDPH)

NCT06711731CerebroSpinal Fluid (CSF) Leak

University Hospital Freiburg

Observational

2,000

Freiburg im Breisgau

2024-11-04

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896Scleroderma, Diffuse

DrugsRapcabtagene autoleucel·Rituximab

Novartis Pharmaceuticals

Phase 2

Freiburg im Breisgau, Göttingen, Leipzig, Halle, Jena, Berlin, Lübeck, Mainz

2024-10-29

Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Irinotecan

Janssen Research & Development, LLC

Phase 3

1,000

Berlin, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg, Mainz

2024-10-18

Active, closed

Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

NCT05888922Androgenetic Alopecia, Female Pattern Baldness

DrugMinoxidil

Industrial Farmacéutica Cantabria, S.A.

Phase 3

520

Bad Bentheim, Berlin, Bochum, Darmstadt, Dresden, Düsseldorf, Frankfurt, Freiburg im Breisgau

2024-10-17

Recruiting

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

NCT06081244Triple Negative Breast Cancer

DrugsSacituzumab Govitecan·Keytruda·Pembrolizumab

Women's Cancer Study Group GmbH

Phase 3

348

Baden-Baden, Böblingen, Freiburg im Breisgau, Heilbronn, Tübingen, Ulm, Weinheim, Augsburg

2024-10-10

Recruiting

THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

NCT06559891Hypertension

SoniVie Inc.

Not applicable

261

Dresden, Erlangen, Frankfurt, Freiburg im Breisgau, Hamburg, Herne, Homburg, Leipzig

2024-10-03

Active, closed

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951Melanoma

DrugsFianlimab·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

151

Freiburg im Breisgau, Ulm, Munich, Regensburg, Würzburg, Giessen, Buxtehude, Bochum

2024-09-18

Recruiting

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542Crohn's Disease

DrugsTrosunilimab·Lutikizumab·Risankizumab

AbbVie

Phase 2

590

Freiburg im Breisgau, Mannheim, Ulm, Erlangen, Munich, Regensburg, Frankfurt am Main, Fulda

2024-09-04

Recruiting

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

NCT06343792Steroid Refractory GVHD

DrugRLS-0071

ReAlta Life Sciences, Inc.

Phase 2

Freiburg im Breisgau

2024-08-31

Recruiting

Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL

NCT05583071Non-Hodgkin Lymphoma

DrugsTafasitamab·Methotrexate·Lenalidomide·Rituximab

University of Cologne

Phase 2

Stuttgart, Freiburg im Breisgau, Cologne, Hamburg, Essen, Berlin

2024-08-23

Active, closed

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT06413498Multiple Myeloma

DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib

Kite, A Gilead Company

Phase 3

452

Berlin, Cologne, Essen, Freiburg im Breisgau, Hamburg, Leipzig, München, Tübingen

2024-08-23

Recruiting

One-Month DAPT in CABG Patients

NCT05997693Chronic Coronary Disease

DrugsTicagrelor·Aspirin

Weill Medical College of Cornell University

Phase 3

700

Düsseldorf, Essen, Freiburg im Breisgau, Giessen, Jena, München, Stuttgart

2024-08-15

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Berlin, Bonn, Cologne, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg

2024-08-12

Recruiting

Multimodal Phenotyping In Patients Referred With Acute Cardiac faiLurE

NCT07515508Cardiogenic Shock, Acute Heart Failure (AHF)

University Heart Center Freiburg - Bad Krozingen

Observational

600

Bad Krozingen, Freiburg im Breisgau, Nuremberg, Villingen-Schwenningen

2024-08-07

Recruiting

VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

NCT06257706Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn

DrugVedolizumab

Alimentiv Inc.

Phase 4

304

Augsburg, Frankfurt am Main, Lüneburg, Kiel, Freiburg im Breisgau

2024-08-07

By invitation

Long-term Safety and Tolerability of BHV-7000

NCT06443463Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2

660

Freiburg im Breisgau, Kehl, Ulm, Erlangen, München, Bernau bei Berlin, Marburg, Osnabrück

2024-07-30

Active, closed

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

NCT06506916Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis

DrugBimekizumab

UCB Biopharma SRL

Phase 3

Berlin, Frankfurt am Main, Freiburg im Breisgau

2024-07-29

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575Biliary Tract Cancer

DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin

Jazz Pharmaceuticals

Phase 3

286

Freiburg im Breisgau, Heidelberg, Tübingen, München, Frankfurt am Main, Hanover, Dresden, Lübeck

2024-07-19

Recruiting

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients

NCT06284590Melanoma Stage III, Melanoma Stage IV

DrugsDaromun·L19IL2·Onfekafusp alfa·Keytruda

Philogen S.p.A.

Phase 2

162

Essen, Freiburg im Breisgau, Kiel, Tübingen

2024-07-12

Recruiting

Case Series on the Clinical Performance of VA Clavicle and Clavicle Hook Plate 2.7 Systems

NCT04921865Clavicle, Acromioclavicular Joint, Fracture

AO Innovation Translation Center

Observational

Freiburg im Breisgau, Münster

2024-07-10

Recruiting

Combination of Hypothermia and Thrombectomy in Acute Stroke

NCT06301412Ischemic Stroke, Large Vessel Occlusion, Endovascular Treatment

University of Freiburg

Phase 3

400

Freiburg im Breisgau

2024-07-07

Not yet open

Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging

NCT03865277Head and Neck Squamous Cell Carcinoma

Technische Universität Dresden

Phase 2

276

Freiburg im Breisgau, Heidelberg, Mannheim, Würzburg, Dresden, Leipzig, Berlin, München

2024-07-01

Recruiting

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

NCT06102057Stage III Non-small Cell Lung Cancer, Locally Advanced, Unresectable

TheraOp

Phase 2

110

Dresden, Essen, Freiburg im Breisgau, Göttingen, Homburg, Mönchengladbach, München, Oldenburg

2024-07-01

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Berlin, Bochum, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hanover, Kiel

2024-06-29

Active, closed

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

NCT06331312Polymyalgia Rheumatica

DrugSecukinumab

Novartis Pharmaceuticals

Phase 3

162

Freiburg im Breisgau, Würzburg, Berlin, Herne

2024-06-28

Active, closed

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 3

1,400

Freiburg im Breisgau, Tübingen, Erlangen, Memmingen, Darmstadt, Bad Bentheim, Rostock, Bochum

2024-06-27

Recruiting

A Registry-study of ELZONRIS in Participants With BPDCN

NCT07785154Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

DrugTagraxofusp

Stemline Therapeutics, Inc.

Observational

Augsburg, Bielefeld, Chemnitz, Frankfurt, Freiburg im Breisgau, Halle, Hamburg, Kiel

2024-06-26

Recruiting

Spinal CSF Leaks in Chronic Subdural Hematoma

NCT06323434Chronic Subdural Hematoma

University of Freiburg

Observational

220

Freiburg im Breisgau

2024-06-24

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Freiburg im Breisgau, Ludwigsburg, Tübingen, Erlangen, Munich, Potsdam, Georgsmarienhütte, Hanover

2024-06-24

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

Bad Nauheim, Berlin, Bonn, Freiburg im Breisgau, Herne, München, Tübingen

2024-06-20

Recruiting

Developing Strategies to Facilitate Consent of Legally Authorized Representatives to Clinical Trials

NCT06471400Critical Illness, Loss of Consciousness

University Hospital Freiburg

Not applicable

Freiburg im Breisgau

2024-06-18

Active, closed

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

NCT06284122Follicular Lymphoma

DrugsBendamustin·Mosunetuzumab·Vincrystine·Obinutuzumab

The Lymphoma Academic Research Organisation

Phase 3

790

Amberg, Bamberg, Berlin, Bremen, Chemnitz, Düsseldorf, Frankfurt, Freiburg im Breisgau

2024-06-07

Recruiting

Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.

NCT06163573Patellofemoral Osteoarthritis

DrugsN-Tec·Platelet rich plasma

University Hospital, Basel, Switzerland

Phase 2

Freiburg im Breisgau, Würzburg

2024-06-06

Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis

DrugsNavtemadlin·Jakavi·Ruxolitinib

Kartos Therapeutics, Inc.

Phase 3

600

Düsseldorf, Freiburg im Breisgau, Halle, Hamburg, Hanover, Heidelberg, Jena, Kiel

2024-06-03

Recruiting

Prospective Registry of Patients Undergoing Cardiac CT With NAEOTOM Alpha PCD-CT Before TAVI Procedure

NCT07016477Coronary Artery Disease, Aortic Valve Stenosis, Tomography, X-Ray Computed

Semmelweis University

Observational

1,000

Freiburg im Breisgau, Mainz, Tübingen

2024-06-01

Active, closed

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

NCT06401044Thyroid Eye Disease

DrugAMG 732

Amgen

Phase 1/2

Essen, Frankfurt am Main, Freiburg im Breisgau, Leipzig

2024-05-30

Recruiting

Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases

NCT06520774Aortic Arch Aneurysm, Penetrating Aortic Ulcer

Lifetech Scientific (Shenzhen) Co., Ltd.

Not applicable

103

Freiburg im Breisgau

2024-05-30

Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

DrugPegozafermin

89bio, Inc.

Phase 3

762

Chemnitz, Frankfurt, Freiburg im Breisgau, Hanover, Homburg, Münster

2024-05-24

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Freiburg im Breisgau, Karlsruhe, Chemnitz, Berlin, Frankfurt am Main, Hamburg

2024-05-19

Recruiting

Hearing and Structure Preservation Via ECochG

NCT06268340Hearing Loss, Sensorineural, Severe-to-profound Hearing Loss

Advanced Bionics AG

Not applicable

102

Freiburg im Breisgau

2024-05-15

Active, closed

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2/3

390

Freiburg im Breisgau, Kehl, Ulm, Erlangen, Bernau bei Berlin, Marburg, Osnabrück, Bielefeld

2024-05-13

Active, closed

A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

NCT06294925Colitis, Ulcerative

DrugEtrasimod

Pfizer

Observational

360

Freiburg im Breisgau, Kassel, Aachen, Andernach, Berlin, Cologne, Dachau, Frankfurt am Main

2024-05-08

Active, closed

A Study Evaluating APG777 in Atopic Dermatitis

NCT06395948Atopic Dermatitis

DrugAPG777

Apogee Therapeutics, Inc.

Phase 2

470

Freiburg im Breisgau, Heidelberg, Tübingen, Augsburg, München, Blankenfelde-Mahlow, Darmstadt, Frankfurt am Main

2024-04-29

Active, closed

Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer

NCT06178445Biliary Tract Cancer, HER2 Gene Mutation, HER2

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2

Augsburg, Berlin, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg, Hanover, München

2024-04-17

Recruiting

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

NCT05791409CLL/SLL

DrugsEpcoritamab·Venetoclax

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 1/2

112

Berlin, Cologne, Freiburg im Breisgau, Greifswald, Halle, Kiel, Münster, Stuttgart

2024-04-15

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

NCT06357533Non-Small Cell Lung Cancer

DrugsRilvegostomig·Dato-DXd·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

675

Berlin, Bonn, Cologne, Düsseldorf, Essen, Freiburg im Breisgau, Gauting, Georgsmarienhütte

2024-04-11

Active, closed

Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma

NCT05871021Glioblastoma

University Hospital Tuebingen

Phase 2

107

Augsburg, Cologne, Frankfurt, Freiburg im Breisgau, Leipzig, Mannheim, Munich, Regensburg

2024-04-10

Not yet open

Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)

NCT05587621ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction, LDL-cholesterol

Jena University Hospital

Not applicable

300

Jena, Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Halle, Homburg

2024-04-01

Active, closed

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

NCT06200207Heart Failure, Systemic Inflammation

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

673

Bremen, Dresden, Elsterwerda, Erfurt, Frankfurt, Freiburg im Breisgau, Fulda, Homburg

2024-04-01

Recruiting

Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study 2

NCT06025123Out-Of-Hospital Cardiac Arrest, Hypothermia, Ventricular Fibrillation

Karolinska Institutet

Not applicable

1,022

Bamberg, Freiburg im Breisgau, Halle, Kandel

2024-03-27

Recruiting

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

NCT06205121Pulmonary Sarcoidosis

Molecure S.A.

Phase 2

Essen, Freiburg im Breisgau, Mainz-GE

2024-03-21

Recruiting

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

100

Berlin, Freiburg im Breisgau, Sankt Augustin

2024-03-14

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

DrugPegozafermin

89bio, Inc.

Phase 3

1,350

Chemnitz, Frankfurt am Main, Freiburg im Breisgau, Hanover, Homburg, Münster

2024-03-13

Recruiting

Randomized Comparison of Skeletonized Versus Pedicled Left Internal Thoracic Artery

NCT05931783Coronary Artery Disease

Medical University Innsbruck

Not applicable

1,350

Essen, Freiburg im Breisgau, Giessen, Jena

2024-03-12

Recruiting

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

NCT05827081Early Breast Cancer

DrugsLeuprolide·Goserelin·Exemestane·Ribociclib

Novartis Pharmaceuticals

Phase 3

1,444

Freiburg im Breisgau, Munich, Regensburg, Weiden in Der Oberpfalz, Langen, Hildesheim, Bergisch Gladbach, Bielefeld

2024-02-28

Recruiting

Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL

NCT06134492Pneumonia, Viral, Ventilator Associated Pneumonia, Community-acquired Pneumonia, Herpes Simplex

DrugAcyclovir

Jena University Hospital

Phase 3

616

Freiburg im Breisgau, Heidelberg, Tübingen, Augsburg, München, Nuremberg, Regensburg, Rosenheim

2024-02-20

Recruiting

Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

NCT05933057Duchenne Muscular Dystrophy

DrugHydroxyurea

Italfarmaco

Phase 3

138

Berlin, Essen, Freiburg im Breisgau, Hamburg

2024-02-19

Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575Multiple Myeloma

DrugsElotuzumab·Elranatamab·Carfilzomib·Pomalidomide

Pfizer

Phase 3

492

Freiburg im Breisgau, Stuttgart, Ulm, Nuremberg, Bonn, Berlin, Cottbus, Hamm

2024-02-08

Recruiting

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

NCT05704829HER2-positive Early Breast Cancer

DrugTrastuzumab deruxtecan

Women's Cancer Study Group GmbH

Phase 2

702

Baden-Baden, Freiburg im Breisgau, Tübingen, Ulm, Augsburg, Munich, Bremerhaven, Frankfurt am Main

2024-02-05

Recruiting

PROCARE - PROstate Cancer Real World Evidence Registry

NCT06835218Prostate Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate, Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

UroTrials Company (GmbH)

Observational

5,000

Freiburg im Breisgau, Heidelberg, Mannheim, Nürtingen, Tübingen, Ulm, Augsburg, Bayreuth

2024-01-29

Recruiting

The Pancreatic Enzymes After Gastrectomy Trial

NCT06058442Gastrectomy

University of Leipzig

Phase 3

188

Borna, Cottbus, Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Jena, Leipzig

2024-01-24

Active, closed

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

NCT06143891Chronic Graft Versus Host Disease

DrugsBelumosudil·Prednisolone·Prednisone

Sanofi

Phase 3

260

Berlin, Cologne, Dresden, Freiburg im Breisgau, Hamburg, Kiel, Münster, Regensburg

2024-01-23

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsErbitux·Cetuximab

AVEO Pharmaceuticals, Inc.

Phase 3

410

Berlin, Freiburg im Breisgau, Munich

2024-01-11

By invitation

5-SENSE Score Validation Study

NCT06138808Epilepsy Intractable

Duke University

Observational

400

Freiburg im Breisgau

2024-01-09

Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)

DrugSurovatamig

AstraZeneca

Phase 1/2

255

Berlin, Cologne, Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Halle, Hamburg

2023-12-29

Recruiting

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

1,264

Berlin, Chemnitz, Cologne, Donauwörth, Erfurt, Freiburg im Breisgau, Gauting, Georgsmarienhütte

2023-12-21

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga

Merck Sharp & Dohme LLC

Phase 3

1,314

Freiburg im Breisgau, Heidelberg, Nürtingen, Munich, Regensburg, Marburg, Göttingen, Bergisch Gladbach

2023-12-18

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Berlin, Erlangen, Essen, Freiburg im Breisgau, Greifswald, Hamburg, Hanover, Leipzig

2023-12-14

Recruiting

LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus

NCT05714930Systemic Lupus Erythematosus

Heinrich-Heine University, Duesseldorf

Not applicable

606

Freiburg im Breisgau, Heidelberg, Erlangen, Munich, Frankfurt am Main, Hanover, Düsseldorf, Essen

2023-12-12

Active, closed

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

DrugsGiredestrant·Abemaciclib·Ribociclib·Palbociclib

Hoffmann-La Roche

Phase 3

1,050

Bamberg, Cologne, Düsseldorf, Erlangen, Essen, Freiburg im Breisgau, Heidelberg, Homburg/Saar

2023-12-11

Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

NCT06106945Multiple Myeloma

DrugsElranatamab·Pomalidomide·Dexamethasone

AstraZeneca

Phase 1/2

226

Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Lübeck, Nuremberg, Tübingen, Würzburg

2023-12-05

Recruiting

Multi-professional Care Pathway and Network for the Promotion of Needs-oriented, Resident-oriented Exercise Therapy for Oncological Patients

NCT06185777Cancer, Exercise, Implementation

University Hospital Heidelberg

Not applicable

2,500

Freiburg im Breisgau, Heidelberg, Tübingen, Frankfurt am Main, Mainz, Dresden, Berlin

2023-12-01

Recruiting

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

NCT05948943Lymphatic Malformations

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2/3

232

Freiburg im Breisgau, Mannheim, Cologne, Leipzig, Berlin, Ulm

2023-11-24

Recruiting

Pretreatment to Promote Graft Survival After Subsequent High-risk Corneal Transplantation [CrossCornealVision]

NCT05870566Corneal Transplantation

Claus Cursiefen

Not applicable

110

München, Cologne, Düsseldorf, Homburg, Berlin, Freiburg im Breisgau, Rostock

2023-11-20

Active, closed

Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

NCT06042478Chronic Spontaneous Urticaria

DrugsOmalizumab·Remibrutinib

Novartis Pharmaceuticals

Phase 3

470

Freiburg im Breisgau, Munich, Hamburg, Göttingen, Stade, Dresden, Leipzig, Halle

2023-11-15

Active, closed

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

NCT06075706Steroid-refractory Acute Graft-versus-host Disease

DrugMC0518

medac GmbH

Phase 2

Aachen, Essen, Frankfurt, Freiburg im Breisgau, Giessen, Hanover, Jena, Leipzig

2023-11-13

Active, closed

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT05925803Systemic Sclerosis, Scleroderma

AstraZeneca

Phase 3

314

Freiburg im Breisgau, Mainz, Minden, Münster, Tübingen

2023-11-08

Active, closed

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915Sjogrens Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

612

Freiburg im Breisgau, Würzburg, Ludwigshafen, Cologne, Dresden, Berlin, Erlangen, Hanover

2023-10-27

Active, closed

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

NCT05984277Metastatic Non-small Cell Lung Cancer

DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin

AstraZeneca

Phase 3

895

Berlin-Zehlendorf, Bonn, Braunschweig, Dresden, Freiburg im Breisgau, Gauting, Georgsmarienhütte, Gütersloh

2023-10-24

Active, closed

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

NCT05598333Congestive Heart Failure

AskBio Inc

Phase 2

150

München, Berlin, Freiburg im Breisgau, Hanover, Heidelberg, Kiel

2023-10-20

Active, closed

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

NCT06095115Plaque Psoriasis

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

684

Bad Bentheim, Berlin, Bonn, Dresden, Dülmen, Düsseldorf, Frankfurt am Main, Freiburg im Breisgau

2023-10-12

Recruiting

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

NCT05609630Juvenile Idiopathic Arthritis

DrugsUpadacitinib·Tocilizumab

AbbVie

Phase 3

Freiburg im Breisgau, Sankt Augustin, Sendenhorst, Berlin, Hamburg

2023-10-02

Recruiting

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

NCT06043011Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL)

iOMEDICO AG

Observational

2,950

Freiburg im Breisgau

2023-09-27

Active, closed

RCT to Evaluate STERN FIX Device as a Sternal Stabilization System in Patients After Sternotomy

NCT05953259Median Sternotomy

NEOS Surgery

Not applicable

Freiburg im Breisgau

2023-09-27

Recruiting

Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)

NCT06094101Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma

University Hospital Tuebingen

Phase 1/2

Essen, Frankfurt am Main, Freiburg im Breisgau, Tübingen

2023-09-19

Active, closed

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

NCT05946941Sjögren's Syndrome

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

774

Munich, Berlin, Freiburg im Breisgau, Hamburg, Tübingen, Würzburg

2023-09-11

Active, closed

Avacostar - (PASS)

NCT05897684ANCA-associated Vasculitis

Vifor Fresenius Medical Care Renal Pharma

Observational

507

Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Göttingen, Hamburg, Hanover

2023-09-11

Recruiting

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

NCT05722938Community-acquired Pneumonia

Biotest

Phase 3

590

Freiburg im Breisgau, Hanover, Essen, Berlin, Hamburg

2023-09-09

Recruiting

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239Metastatic Breast Cancer

DrugsPhesgo·Inavolisib

Hoffmann-La Roche

Phase 3

230

Amberg, Berlin, Bottrop, Düsseldorf, Erfurt, Erlangen, Freiburg im Breisgau, München

2023-09-08

Recruiting

Cardiac Biomarkers for the Quantification of Myocardial Damage After Cardiac Surgery

NCT06066970Cardiac Valve Disease

Jena University Hospital

Observational

100

Freiburg im Breisgau, Ulm, Münster, Halle, Jena

2023-09-05

Recruiting

Video Capsule Endoscopy for Detection of Gastrointestinal Bleeding in the Small Bowel

NCT05949268GastroIntestinal Bleeding

University Hospital Freiburg

Observational

1,300

Freiburg im Breisgau

2023-09-01

Active, closed

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.

NCT05921994Hidradenitis Suppurativa

Novartis Pharmaceuticals

Observational

436

Freiburg im Breisgau, Rheinstetten, Haßfurt, Kulmbach, Lauf an der Pegnitz, Nuremberg, Panketal, Hamburg

2023-08-10

Recruiting

Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients

NCT06830421Primary Central Nervous System Lymphoma

University Hospital Freiburg

Phase 3

340

Freiburg im Breisgau, Stuttgart, Aachen, Augsburg, Berlin, Bielefeld, Bochum, Braunschweig

2023-08-09

Recruiting

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

NCT05890677Lymphedema, Breast Cancer

University Hospital, Basel, Switzerland

Not applicable

280

Bochum, Düsseldorf, Erlangen, Essen, Frankfurt, Freiburg im Breisgau, Ludwigshafen am Rhein, Nuremberg

2023-07-14

Active, closed

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182Hidradenitis Suppurativa

DrugUpadacitinib

AbbVie

Phase 3

1,328

Freiburg im Breisgau, Erlangen, Regensburg, Würzburg, Frankfurt am Main, Bad Bentheim, Bramsche, Düsseldorf

2023-06-21

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862Breast Cancer

DrugsBupropion·Omeprazole·Alpelisib·Inavolisib

Hoffmann-La Roche

Phase 3

420

Aachen, Bielefeld, Essen, Freiburg im Breisgau, Georgsmarienhütte, Göttingen, Hamburg, Hanover

2023-06-07

Recruiting

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma

DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin

AstraZeneca

Phase 1/2

622

Berlin, Essen, Freiburg im Breisgau, Hanover, Leipzig, Mannheim, Regensburg

2023-06-05

Recruiting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction

DrugVericiguat

Merck Sharp & Dohme LLC

Phase 2/3

342

Freiburg im Breisgau, Heidelberg, Erlangen, Hanover, Berlin

2023-05-31

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

NCT05748171ACUTE LYMPHOBLASTIC LEUKEMIA

DrugInotuzumab Ozogamicin

Pfizer

Phase 2

100

Freiburg im Breisgau, Ulm, Würzburg, Frankfurt am Main, Hanover, Essen, Münster, Kiel

2023-05-17

Active, closed

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

NCT05876754Cholangiocarcinoma

DrugIvosidenib

Servier Affaires Médicales

Phase 3

299

Berlin, Dresden, Düsseldorf, Frankfurt, Freiburg im Breisgau, Hanover, München

2023-05-03

By invitation

An Open-label Study of XEN1101 in Epilepsy

NCT05718817Focal Epilepsy, Tonic-Clonic Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

880

Aachen, Bielefeld, Frankfurt, Freiburg im Breisgau, Marburg, München, Ulm

2023-04-25

Active, closed

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

NCT05624749Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

288

Freiburg im Breisgau, Cologne, Leipzig, Herne, Mainz

2023-04-21

Active, closed

Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab

NCT05626855Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA

DrugApitegromab

Scholar Rock, Inc.

Phase 3

238

Bonn, Essen, Freiburg im Breisgau, Munchen, Bayern

2023-04-17

Recruiting

The DefiPace Study

NCT04804748Post-operative Atrial Fibrillation POAF

Institut für Pharmakologie und Präventive Medizin

Observational

450

Erlangen, Nuremberg, Würzburg, Oldenburg, Dresden, Freiburg im Breisgau, Hanover, Jena

2023-03-28

Active, closed

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

NCT05714202Bladder Cancer

DrugsTAR-200·Cetrelimab

Janssen Research & Development, LLC

Phase 3

1,135

Cologne, Duisburg, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Markkleeberg, Mettmann

2023-03-23

Active, closed

Thoraflex Hybrid and Relay Extension Post-Approval Study

NCT05639400Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm

Vascutek Ltd.

Observational

352

Freiburg im Breisgau

2023-03-17

Recruiting

Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia

NCT05366218ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory

DrugTafasitamab

University Hospital Tuebingen

Phase 1/2

Freiburg im Breisgau, Tübingen, Ulm, München, Hamburg, Düsseldorf, Berlin, Essen

2023-03-08

Active, closed

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

NCT05201066Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

DrugsSpartalizumab·Decitabine·Azacitidine·Venetoclax

Novartis Pharmaceuticals

Phase 2

Freiburg im Breisgau

2023-02-28

Active, closed

A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD

NCT05933200Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Ultragenyx Pharmaceutical Inc

Phase 3

Freiburg im Breisgau

2023-02-28

Active, closed

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma

DrugsTovorafenib·Carboplatin

Day One Biopharmaceuticals, Inc.

Phase 3

418

Freiburg im Breisgau, Augsburg, Erlangen, Würzburg, Frankfurt am Main, Hanover, Essen, Leipzig

2023-02-27

Active, closed

VIATORR Device Registry

NCT05661331Chronic Liver Disease

W.L.Gore & Associates

Observational

196

Freiburg im Breisgau, Münster

2023-02-21

Recruiting

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

NCT05667142Primary Generalized Tonic-Clonic Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

160

Aachen, Berlin, Bielefeld, Frankfurt, Freiburg im Breisgau, Marburg, München, Radeberg

2023-02-14

Recruiting

Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy

NCT05551299Hilar Cholangiocarcinoma

University of Leipzig

Phase 4

258

Aachen, Augsburg, Berlin, Bonn, Frankfurt, Freiburg im Breisgau, Greifswald, Halle

2023-02-10

Recruiting

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

NCT05682378Heterozygous or Homozygous Familial Hypercholesterolemia

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

195

Frankfurt am Main, Freiburg im Breisgau

2023-02-10

Active, closed

Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis

NCT03843385Ulcerative Colitis, Inflammatory Bowel Diseases

Andreas Stallmach

Phase 3

Jena, Bamberg, Berlin, Dresden, Erlangen, Frankfurt, Freiburg im Breisgau, Fulda

2023-01-31

Active, closed

Study to Assess SLN124 in Patients With Polycythemia Vera

NCT05499013Polycythemia Vera

Silence Therapeutics plc

Phase 1/2

Freiburg im Breisgau, Hanover

2023-01-26

Active, closed

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

NCT05478304Ischemic Stroke, Systemic Embolism

AtriCure, Inc.

Not applicable

6,573

Freiburg im Breisgau, Bad Neustadt an der Saale, Berlin, Bad Rothenfelde, Hamburg

2023-01-25

Active, closed

Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve

NCT05397106Hydrocephalus, Hydrocephalus in Children, NPH (Normal Pressure Hydrocephalus), IIH - Idiopathic Intracranial Hypertension

Integra LifeSciences Corporation

Observational

160

Dortmund, Düsseldorf, Essen, Freiburg im Breisgau, Stuttgart

2023-01-24

Active, closed

ABTECT - Maintenance

NCT05535946Ulcerative Colitis

DrugObefazimod

Abivax S.A.

Phase 3

1,116

Freiburg im Breisgau, Heidelberg, Nürtingen, Pforzheim, Tübingen, Ulm, Erlangen, Munich

2023-01-16

Active, closed

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

NCT05555732Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Pemetrexed·Keytruda·Cisplatin

Daiichi Sankyo

Phase 3

1,170

Berlin, Chemnitz, Essen, Esslingen am Neckar, Freiburg im Breisgau, Giessen, Mannheim, Munich

2023-01-11

Recruiting

Freiburg TIPS Registry

NCT05782556Liver Cirrhosis, Portal Hypertension, Non-Cirrhotic Portal Hypertension, Budd Chiari Syndrome

University Hospital Freiburg

Observational

2,000

Freiburg im Breisgau

2023-01-01

Recruiting

Long-term Evaluation of the Efficacy and Safety of Splentis for the Treatment of Primary Apical Pelvic Organ Prolapse

NCT05042453Pelvic Organ Prolapse

Promedon

Observational

140

Chemnitz, Erfurt, Freiburg im Breisgau, Kassel, Leipzig, Mannheim, Tettnang

2022-12-19

Recruiting

AIO-BNHO Comprehensive Clinico-genomics Database Network - AIO-BNHO CONNECT

NCT05701150Advanced Solid Tumor

AIO-Studien-gGmbH

Observational

3,000

Freiburg im Breisgau, Mannheim, München

2022-12-08

Recruiting

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

NCT05695508Multiple Myeloma

DrugsRamantamig·Talquetamab·Teclistamab·Bortezomib

University of Heidelberg Medical Center

Phase 2

160

Berlin, Chemnitz, Dresden, Düsseldorf, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel

2022-12-01

Recruiting

HRS-AKI Treatment With TIPS in Patients With Cirrhosis

NCT05346393Cirrhosis, Liver, Hepatorenal Syndrome, Acute Kidney Injury, Ascites Hepatic

Jena University Hospital

Not applicable

124

Aachen, Berlin, Dresden, Essen, Freiburg im Breisgau, Halle, Hamburg, Hanover

2022-11-29

Active, closed

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

NCT05456191Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

DrugsAsciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

568

Freiburg im Breisgau, Mannheim, Munich, Würzburg, Frankfurt am Main, Marburg, Paderborn, Velbert

2022-11-21

Active, closed

RESPONDER-HF Trial

NCT05425459Heart Failure, Heart Failure, Diastolic

Corvia Medical

Not applicable

750

Bad Krozingen, Bad Nauheim, Berlin, Cologne, Dresden, Düsseldorf, Freiburg im Breisgau, Göttingen

2022-11-17

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020Multiple Myeloma

DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide

Pfizer

Phase 3

1,060

Freiburg im Breisgau, Tübingen, Ulm, Mainz, Aachen, Braunschweig, Chemnitz, Hamburg

2022-11-10

Active, closed

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT05358249KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer

DrugsOpnurasib·Trametinib·Ribociclib·Cetuximab

Novartis Pharmaceuticals

Phase 1/2

Freiburg im Breisgau

2022-10-24

Active, closed

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

NCT05556512Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

15,374

Bad Homburg, Bad Oeynhausen, Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Hamburg

2022-10-11

Active, closed

A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec

NCT05575011Healthy Volunteer, Muscular Atrophy, Spinal

DrugSalanersen

Biogen

Phase 1

Essen, Freiburg im Breisgau, Heidelberg

2022-10-10

Active, closed

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

NCT05440786Sarcoma, Ewing, Neoplasm Metastasis

DrugsAbemaciclib·Temozolomide·Irinotecan

Eli Lilly and Company

Phase 2

Freiburg im Breisgau, Essen, Berlin

2022-09-20

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484Colitis, Ulcerative

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

577

Berlin, Dresden, Erlangen, Frankfurt, Frankfurt am Main, Freiburg im Breisgau, Fulda, Halle

2022-09-19

Active, closed

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsCeralasertib·Durvalumab·Docetaxel

AstraZeneca

Phase 3

594

Berlin, Freiburg im Breisgau, Gauting, Karlsruhe, Kempten, Löwenstein, Moers

2022-09-15

Active, closed

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05361395Extensive Stage Small Cell Lung Cancer

DrugsTarlatamab·Tecentriq·Etoposide·Atezolizumab

Amgen

Phase 1

184

Dresden, Essen, Freiburg im Breisgau

2022-08-24

Recruiting

Image-guided Focal Dose Escalation- Primary pc Treated With Primary External Beam Hypofract.Stereotactic rt

NCT06330909Prostate Cancer

University Hospital Freiburg

Not applicable

374

Freiburg im Breisgau

2022-08-18

Active, closed

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286Triple Negative Breast Cancer, PD-L1 Positive

DrugsAbraxane·Sacituzumab Govitecan·Taxol·Nab-paclitaxel

Gilead Sciences

Phase 3

443

Berlin, Bonn, Bottrop, Cologne, Erlangen, Essen, Freiburg im Breisgau, Hamburg

2022-07-25

Recruiting

Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy

NCT05442710Sepsis, Severe

Artcline GmbH

Phase 2

142

Freiburg im Breisgau, Regensburg, Bonn, Cologne, Aue, Leipzig, Halle, Kiel

2022-07-24

Active, closed

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

NCT05296798Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Phesgo·Pertuzumab·Trastuzumab

Hoffmann-La Roche

Phase 3

922

Bad Nauheim, Bamberg, Essen, Freiburg im Breisgau, Heidelberg, Hildesheim, Homburg/Saar, Langen

2022-07-18

Active, closed

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

NCT05263934Eosinophilic Granulomatosis With Polyangiitis

DrugsDepemokimab·Mepolizumab

GlaxoSmithKline

Phase 3

163

Freiburg im Breisgau, Minden

2022-07-14

Active, closed

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

NCT05337553Spinal Muscular Atrophy, Neuromuscular Diseases, SMA

DrugTaldefgrobep alfa

Biohaven Pharmaceuticals, Inc.

Phase 3

269

Essen, Freiburg im Breisgau, Munich

2022-07-06

Recruiting

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

NCT05429632Adult Acute Myeloid Leukemia

Priothera SAS

Phase 3

366

Freiburg im Breisgau, Halle, Jena, Leipzig, Munich

2022-06-16

Active, closed

An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

NCT05300724Age-Related Macular Degeneration

Genentech, Inc.

Observational

400

Bonn, Freiburg im Breisgau, Göttingen, Hanover, Leipzig, Münster, Tübingen

2022-05-27

Active, closed

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

NCT05359445Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer

DrugsKeytruda·Pembrolizumab

Immatics Biotechnologies GmbH

Phase 1

Freiburg im Breisgau, Heidelberg, Tübingen, Ulm, Erlangen, Munich, Nuremberg, Regensburg

2022-05-19

Active, closed

RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

NCT05134012Coronary Artery Disease

MedTrace Pharma A/S

Phase 3

215

Freiburg im Breisgau, Hanover

2022-05-08

Recruiting

Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®

NCT05114850Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Insufficiency, Heart Failure

P+F Products + Features GmbH

Observational

450

Freiburg im Breisgau, Friedrichshafen, Heilbronn, Regensburg, Stuttgart, Winnenden

2022-04-20

Active, closed

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs

DrugsAbiraterone·Abemaciclib·Prednisolone·Prednisone

Eli Lilly and Company

Phase 3

925

Freiburg im Breisgau, Heidelberg, Nürtingen, Ulm, Tübingen, Munich, Frankfurt am Main, Duisburg

2022-04-14

Active, closed

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

NCT05270668Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease

DrugTulisokibart

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

154

Freiburg im Breisgau, Bad Nauheim, Hohenfelde B Bad Doberan, Cologne

2022-03-29

Recruiting

Pathogen-microbiome Interaction During Helicobacter Pylori Infection

NCT05121025Helicobacter Pylori Infection

University Hospital Freiburg

Observational

180

Freiburg im Breisgau

2022-03-11

Active, closed

Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)

NCT05051033Mitral Valve Regurgitation

Annetine Gelijns

Not applicable

450

Cologne, Bad Nauheim, Bad Rothenfelde, Berlin, Frankfurt, Freiburg im Breisgau, Hamburg, Heidelberg

2022-02-21

Recruiting

Staphylococcus Aureus Network Adaptive Platform Trial

NCT05137119Staphylococcus Aureus Bacteremia

DrugsBenzylpenicillin·Daptomycin·Cefazolin·Clindamycin

University of Melbourne

Phase 4

8,000

Berlin, Dresden, Freiburg im Breisgau, Magdeburg

2022-02-16

Active, closed

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD

DrugsEylea·Aflibercept

AbbVie

Phase 3

735

Freiburg im Breisgau, Ulm, Bonn, Münster, Ludwigshafen am Rhein, Hamburg, Püttlingen

2022-01-13

Active, closed

A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting

NCT05139836Atopic Dermatitis

AbbVie

Observational

634

Freiburg im Breisgau, Heidelberg, Langenau, Stuttgart, Freising, Memmingen, Munich, Nuremberg

2021-12-13

Active, closed

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

NCT05156281Relapsing Multiple Sclerosis

DrugsTeriflunomide·Remibrutinib

Novartis Pharmaceuticals

Phase 3

1,007

Freiburg im Breisgau, Essen, Hamburg

2021-12-13

Recruiting

High Dose Steroids in Children With Stroke

NCT04873583Paediatric Stroke

DrugsSolu-Medrol·Methylprednisolone·Prednisolone

Insel Gruppe AG, University Hospital Bern

Phase 3

Freiburg im Breisgau, München, Düsseldorf, Münster, Berlin, Hanover

2021-11-16

Recruiting

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

NCT04996875Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)

DrugBezuclastinib

Cogent Biosciences, Inc.

Phase 2

140

Aachen, Freiburg im Breisgau, Lübeck, Mannheim

2021-11-09

Active, closed

Low-dose Atropine for Myopia Control in Children

NCT03865160Myopia, Progressive

DrugAtropine eye

University Eye Hospital, Freiburg

Phase 2/3

302

Ahaus, Bonn, Cologne, Erlangen, Essen, Freiburg im Breisgau, Göttingen, Hamburg

2021-10-19

Active, closed

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

NCT04958239Neoplasms

DrugsEzabenlimab·Pembrolizumab

Boehringer Ingelheim

Phase 1

151

Freiburg im Breisgau, Halle, Stuttgart

2021-10-18

Active, closed

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169Multiple Myeloma

DrugsTeclistamab·Pomalidomide·Bortezomib·Daratumumab

Janssen Research & Development, LLC

Phase 3

587

Dresden, Düsseldorf, Essen, Freiburg im Breisgau, Hamburg, Hamm, Heidelberg, Kiel

2021-10-14

Recruiting

Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)

NCT05112549Leptomeningeal Disease

DrugsOpdivo·Nivolumab

University Hospital Tuebingen

Phase 1

Bonn, Freiburg im Breisgau, Heidelberg, Heilbronn, Mannheim, München, Stuttgart, Tübingen

2021-10-12

Active, closed

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT04895696Systemic Lupus Erythematosus

Beeline Medicines Corporation

Phase 2

248

Cologne, Berlin, Essen, Freiburg im Breisgau

2021-10-11

Active, closed

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT04926818Multiple Sclerosis (MS)

DrugsSiponimod·Fingolimod·Ofatumumab

Novartis Pharmaceuticals

Phase 3

129

Freiburg im Breisgau, Göttingen, Bochum

2021-10-05

Recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462Primary IgA Nephropathy

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

540

Freiburg im Breisgau, Stuttgart, Aachen, Berlin, Essen, Hanover, Heidelberg, Kiel

2021-09-20

Active, closed

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

NCT04909801Rheumatoid Arthritis

DrugsAbatacept·Humira·Adalimumab·Methotrexate

Bristol-Myers Squibb

Phase 3

338

Berlin, Bonn, Freiburg im Breisgau, Hamburg, Planegg

2021-09-15

Active, closed

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893Multiple Myeloma

DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine

Janssen Research & Development, LLC

Phase 3

743

Berlin, Dresden, Freiburg im Breisgau, Hamburg, Heidelberg, Leipzig, Mainz, München

2021-08-19

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor

DrugBelzutifan

Merck Sharp & Dohme LLC

Phase 2

355

Freiburg im Breisgau, München, Würzburg, Düsseldorf, Berlin

2021-08-12

Active, closed

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

NCT04674683Unresectable or Metastatic Melanoma, Progressive Brain Metastasis

DrugsChidamide·Nivolumab

HUYABIO International, LLC.

Phase 3

450

Berlin, Cologne, Dresden, Erfurt, Essen, Freiburg im Breisgau, Heidelberg, Leipzig

2021-08-12

Active, closed

Pulmonary Embolism International THrOmbolysis Study-3

NCT04430569Pulmonary Embolism

DrugAlteplase

Assistance Publique - Hôpitaux de Paris

Phase 3

800

Bad Krozingen, Berlin, Cologne, Dresden, Düsseldorf, Freiburg im Breisgau, Greifswald, Hanover

2021-08-04

Active, closed

Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism

NCT04790370Pulmonary Embolism

DrugsLMWH·Heparin

Boston Scientific Corporation

Phase 4

544

Aachen, Bielefeld, Bonn, Chemnitz, Freiburg im Breisgau, Immenstädt, Lübeck, Mainz

2021-08-02

By invitation

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

NCT04976322Systemic Lupus Erythematosus

UCB Biopharma SRL

Phase 3

760

Cologne, Freiburg im Breisgau, Herne, Leipzig, Tübingen, Vogelsang-gommern

2021-07-27

Active, closed

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

NCT04657289Neovascular Age-related Macular Degeneration (nAMD)

DrugRanibizumab

Hoffmann-La Roche

Phase 3

451

Bonn, Cologne, Cottbus, Freiburg im Breisgau, Hamburg, Ludwigshafen, München, Münster

2021-07-14

Active, closed

Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease

NCT05043103Advanced Parkinson Disease

Britannia Pharmaceuticals Ltd.

Observational

312

Bad Segeberg, Beelitz-Heilstätten, Berlin, Cologne, Coppenbrügge, Essen, Freiburg im Breisgau, Göttingen

2021-07-06

Active, closed

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Abemaciclib·Ribociclib

AstraZeneca

Phase 3

315

Ansbach, Augsburg, Bonn, Chemnitz, Dresden, Erlangen, Essen, Freiburg im Breisgau

2021-06-30

By invitation

Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

NCT04451044Coronary Artery Disease, Ischemic Heart Disease

Philips Clinical & Medical Affairs Global

Not applicable

3,212

Berlin, Erlangen, Essen, Freiburg im Breisgau

2021-06-17

Active, closed

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 3

893

Augsburg, Dresden, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Georgsmarienhütte, Hanover

2021-05-10

Active, closed

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

NCT04784715Breast Cancer; HER2-positive; Metastatic

DrugsPertuzumab·Trastuzumab deruxtecan·Trastuzumab

AstraZeneca

Phase 3

1,157

Berlin, Dresden, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg

2021-04-26

Active, closed

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124Bladder Cancer

DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

808

Freiburg im Breisgau, Tübingen, Regensburg, Würzburg, Herne, Münster, Dresden, Halle

2021-04-21

Active, closed

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

NCT04589650PIK3CA-related Overgrowth Spectrum (PROS)

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2

236

Freiburg im Breisgau, Düsseldorf, Leipzig, Hamburg, Heidelberg

2021-04-19

Active, closed

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

NCT04527380Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis

DrugsIxekizumab·Adalimumab

Eli Lilly and Company

Phase 3

101

Freiburg im Breisgau, Sankt Augustin, Sendenhorst, Berlin, Bremen, Hamburg

2021-04-13

Recruiting

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

NCT04715646Epilepsy

DrugBrivaracetam

UCB Biopharma SRL

Phase 3

Freiburg im Breisgau

2021-03-11

Active, closed

Prospective Long-term Evaluation of the Efficacy and Safety of Calistar S for Transvaginal Pelvic Organ Prolapse Repair

NCT03821142Pelvic Organ Prolapse

Promedon

Not applicable

180

Erfurt, Berlin, Freiburg im Breisgau, Leipzig, Tettnang, Tübingen

2021-03-10

Active, closed

Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases

NCT04276701Systemic Lupus Erythematosus

DrugBlood sample

University Hospital, Bordeaux

Not applicable

500

Freiburg im Breisgau

2021-03-10

Active, closed

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

NCT04586231Carcinoma, Renal Cell

DrugsBelzutifan·Cabozantinib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

747

Freiburg im Breisgau, Heidelberg, Nuremberg, Frankfurt am Main, Aachen, Homburg/ Saar, Halle, Erfurt

2021-02-25

Active, closed

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung

DrugsTNO155·Opnurasib·Tislelizumab

Novartis Pharmaceuticals

Phase 1/2

344

Freiburg im Breisgau, Cologne, Dresden, Essen

2021-02-24

Recruiting

PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches

NCT04545502Aneurysm, Dissection, Aortic Root Aneurysm, Aortic Root Dissection

Vascutek Ltd.

Observational

2,000

Berlin, Bonn, Freiburg im Breisgau, Hamburg, Leipzig, Mainz, Munich

2021-02-17

Active, closed

Go Fit Fast, Recovery Trajectory Using PROMIS®, Linking PROMIS®

NCT04113044Hip Fractures, Tibial Fractures, Ankle Fractures, Humeral Fracture, Proximal

AO Innovation Translation Center

Observational

1,500

Berlin, Freiburg im Breisgau, Homburg, Murnau am Staffelsee, Tübingen

2021-02-01

Active, closed

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659Sickle Cell Disease

DrugEtavopivat

Forma Therapeutics, Inc.

Phase 3

450

Berlin, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg, Regensburg

2021-01-29

Active, closed

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Palbociclib

AstraZeneca

Phase 3

1,371

Berlin, Dessau-RoBlau, Essen, Freiburg im Breisgau, Mönchengladbach, München, Münster, Regensburg

2021-01-28

Active, closed

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

NCT04656652Non-small Cell Lung Cancer

DrugsDato-DXd·Docetaxel

Daiichi Sankyo

Phase 3

605

Berlin, Cologne, Frankfurt am Main, Freiburg im Breisgau, Gauting, Heidelberg, Hemer, Kempten

2020-12-21

Active, closed

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT04351555Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib·Pemetrexed·Cisplatin

AstraZeneca

Phase 3

358

Berlin, Bielefeld, Cologne, Esslingen a.N., Freiburg im Breisgau, Gauting, Georgsmarienhütte, Halle

2020-12-16

Active, closed

WATER III: Aquablation vs. Transurethral Laser Enucleation of Large Prostates (80 - 180mL) in Benign Prostatic Hyperplasia

NCT04801381BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms

University of Bonn

Not applicable

202

Freiburg im Breisgau, Bochum, Bonn

2020-12-16

Active, closed

Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients

NCT04246684Rectal Cancer Stage III

DrugsFolinic acid·Fluorouracil·Adrucil·Capecitabine

Prof. Dr. med. Claus Rödel

Phase 3

702

Esslingen am Neckar, Freiburg im Breisgau, Mannheim, Mutlangen, Offenburg, Ostfildern, Stuttgart, Tübingen

2020-11-05

Recruiting

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

NCT04111978Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC)

DrugLetrozole

Swiss GO Trial Group

Phase 3

540

Berlin, Cologne, Deggendorf, Dresden, Düsseldorf, Essen, Esslingen am Neckar, Freiburg im Breisgau

2020-11-05

Active, closed

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

NCT04595565HER2-negative Breast Cancer, Triple Negative Breast Cancer

DrugsXeloda·Sacituzumab Govitecan·Paraplatin·Capecitabine

GBG Forschungs GmbH

Phase 3

1,332

Böblingen, Esslingen am Neckar, Freiburg im Breisgau, Karlsruhe, Mannheim, Nürtingen, Reutlingen, Ulm

2020-10-28

Active, closed

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

NCT04544449Multiple Sclerosis, Primary Progressive

DrugsFenebrutinib·Ocrelizumab

Hoffmann-La Roche

Phase 3

985

Berlin, Böblingen, Dresden, Freiburg im Breisgau, München, Tübingen, Wiesbaden

2020-10-26

Active, closed

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

NCT04464226Cancer

DrugDarolutamide

Bayer

Phase 3

402

Emmendingen, Freiburg im Breisgau, Mühlacker, Nürtingen, Reutlingen, Tübingen, Erlangen, Braunschweig

2020-10-20

Active, closed

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

NCT04590963Squamous Cell Carcinoma of the Head and Neck

DrugsMonalizumab·Erbitux·Cetuximab

AstraZeneca

Phase 3

370

Berlin, Essen, Freiburg im Breisgau, Hanover, Leipzig, Ulm, Würzburg

2020-10-02

Active, closed

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611Crohn's Disease (CD)

DrugsSkyrizi·Risankizumab·Ustekinumab

AbbVie

Phase 3

527

Freiburg im Breisgau, Mannheim, Ulm, Erlangen, Regensburg, Frankfurt am Main, Hanover, Lüneburg

2020-09-30

Active, closed

Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)

NCT04483739Multiple Myeloma

European Myeloma Network B.V.

Phase 3

302

Freiburg im Breisgau, Hamburg, München

2020-09-25

Active, closed

Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

NCT04565054Breast Cancer Female

DrugAbemaciclib

Women's Cancer Study Group GmbH

Phase 3

1,260

Freiburg im Breisgau, Heilbronn, Ravensburg, Ulm, Weinheim, Baden-Baden, Tübingen, Augsburg

2020-09-02

Active, closed

Combination of Ranibizumab and Targeted Laser Photocoagulation

NCT04444492Central Retinal Vein Occlusion With Macular Edema

DrugsLucentis·Ranibizumab

University of Giessen

Phase 3

Freiburg im Breisgau, Giessen, Hanover, Leipzig, Ludwigshafen, Marburg, München, Münster

2020-08-25

Active, closed

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

NCT04221477Lupus Nephritis

DrugsDiphenhydramine·Acetaminophen·Methylprednisolone·Obinutuzumab

Hoffmann-La Roche

Phase 3

271

Berlin, Dresden, Freiburg im Breisgau, Mainz, Tübingen

2020-08-10

Active, closed

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425Advanced or Metastatic Breast Cancer

DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel

AstraZeneca

Phase 3

866

Berlin, Dresden, Freiburg im Breisgau, Hanover, München, Münster, Velbert

2020-07-24

Active, closed

A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

NCT03992430Muscular Dystrophy, Duchenne

DrugEteplirsen

Sarepta Therapeutics, Inc.

Phase 3

160

Berlin, Essen, Freiburg im Breisgau

2020-07-13

Recruiting

OP2C : Prialt® Observatory in Clinical Practice

NCT04321408Refractory Pain

DrugZiconotide

Institut Cancerologie de l'Ouest

Observational

300

Freiburg im Breisgau, Giessen, Jena

2020-07-10

Recruiting

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

NCT04256317Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia

DrugsVenclexta·Azacitidine·Venetoclax

Taiho Oncology, Inc.

Phase 2/3

316

Freiburg im Breisgau, Heidelberg, Braunschweig, Halle

2020-05-21

Active, closed

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

NCT04108195Multiple Myeloma

DrugsTalquetamab·Darzalex·Teclistamab·Pomalidomide

Janssen Research & Development, LLC

Phase 1

290

Freiburg im Breisgau, Hamburg, Heidelberg, Würzburg

2020-02-21

Recruiting

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

NCT05999994Neoplasms, Child, Adolescent

DrugsRamucirumab·Vinorelbine·Abemaciclib·Temozolomide

Eli Lilly and Company

Phase 2

105

Essen, Freiburg im Breisgau, Hamburg

2020-01-22

Active, closed

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

NCT04175600Hypertension, Pulmonary

DrugSelexipag

Actelion

Phase 3

138

Freiburg im Breisgau, Heidelberg, Leipzig, München

2020-01-16

Active, closed

Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

NCT04230759Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage II

DrugDurvalumab

Goethe University

Phase 2

180

Darmstadt, Dresden, Freiburg im Breisgau, Essen, Kiel, Leipzig, Magdeburg, Mainz

2020-01-07

Recruiting

Terumo Aortic Global Endovascular Registry

NCT04246463Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery

Vascutek Ltd.

Observational

1,000

Augsburg, Berlin, Chemnitz, Freiburg im Breisgau, Göttingen, Lingen, Münster, Tübingen

2019-12-17

Active, closed

Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer

NCT04141709Oligometastatic Disease, Prostatic Cancer, Castration-Resistant

Technische Universität Dresden

Not applicable

Dresden, Freiburg im Breisgau, Heidelberg, Tübingen

2019-12-01

Active, closed

NCT04232241Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes

Universitätsklinikum Hamburg-Eppendorf

Phase 2

167

Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Hamburg, Hanover, Leipzig, Münster

2019-11-14

Active, closed

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

NCT04041050Myeloproliferative Neoplasm

DrugsNavitoclax·Celebrex·Celecoxib·Ruxolitinib

AbbVie

Phase 1

Freiburg im Breisgau, Kassel, Rostock, Berlin

2019-11-08

Active, closed

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

NCT04157348Eosinophilic Granulomatous Vasculitis

DrugsBenralizumab·Mepolizumab

AstraZeneca

Phase 3

140

Bamberg, Freiburg im Breisgau, Hamburg, Kirchheim, Lübeck

2019-10-29

Active, closed

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

NCT03958877Multiple Sclerosis, Relapsing-Remitting

DrugsPlegridy·Avonex

Biogen

Phase 3

152

Freiburg im Breisgau, Göttingen, Bochum, Berlin

2019-10-18

Active, closed

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

NCT03989414Multiple Myeloma

DrugsElotuzumab·Mezigdomide·Isatuximab·Carfilzomib

Celgene

Phase 1/2

424

Freiburg im Breisgau, Hamburg, Heidelberg, München, Würzburg

2019-09-30

Recruiting

Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

NCT04832607AdV Infection, EBV Infection, CMV Infection, Stem Cell Transplant Complications

Tobias Feuchtinger

Phase 3

149

Berlin, Dresden, Düsseldorf, Essen, Freiburg im Breisgau, Hanover, Leipzig, Munich

2019-08-27

Active, closed

Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

NCT03443856Gastric and Esophagogastric Junction Adenocarcinoma

DrugNivolumab and Ipilimumab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

197

Berlin, Essen, Freiburg im Breisgau, Hamburg, Heilbronn, Leipzig, München, Tübingen

2019-07-17

Active, closed

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

NCT04055493Breast Cancer Female

DrugRibociclib

Women's Cancer Study Group GmbH

Phase 3

1,684

Aalen, Baden-Baden, Böblingen, Freiburg im Breisgau, Heilbronn, Ludwigsburg, Tübingen, Ulm

2019-07-02

Active, closed

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

NCT04015141Pediatric Epileptic Syndrome, Partial-onset Seizures

DrugPerampanel

Eisai Inc.

Phase 2

100

Freiburg im Breisgau, Jena, Munich, Radeberg

2019-05-31

Active, closed

Inspiris Resilia Durability Registry

NCT03666741Aortic Valve Stenosis

Institut für Pharmakologie und Präventive Medizin

Observational

400

Freiburg im Breisgau, Leipzig

2019-04-26

Active, closed

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

NCT03768063Cancer

DrugsEmactuzumab·Rucaparib·Cobimetinib·Vemurafenib

Hoffmann-La Roche

Phase 3

1,000

Ulm, Regensburg, Lübeck, Essen, Freiburg im Breisgau, Gauting, Gera, Immenhausen

2019-02-28

Active, closed

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

NCT03796962Focal Epilepsy

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 2

325

Berlin, Bielefeld, Bonn, Frankfurt, Freiburg im Breisgau, Münster, Osnabrück, Regensburg

2019-01-30

Recruiting

De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas

NCT03396718Head-and-neck Squamous Cell Carcinoma

Technische Universität Dresden

Not applicable

304

Tübingen, Essen, Dresden, Berlin, Frankfurt am Main, Freiburg im Breisgau, Heidelberg, München

2018-11-29

Recruiting

GISAR German Interdisciplinary Sarcoma Registry

NCT04122872Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Carcinosarcoma

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Observational

9,000

Tübingen, Erlangen, Bad Saarow, Berlin, Berlin-Spandau, Frankfurt, Freiburg im Breisgau, Göttingen

2018-11-29

Active, closed

Obinutuzumab in Marginal Zone Lymphoma

NCT03322865Marginal Zone Lymphoma

DrugObinutuzumab

Christian Buske

Phase 2

Bochum, Essen, Freiburg im Breisgau, Göttingen, Halle, Koblenz, Mainz, Mannheim

2018-11-23

Active, closed

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

NCT03732820Metastatic Castration-resistant Prostate Cancer

DrugsZytiga·Abiraterone acetate·Olaparib

AstraZeneca

Phase 3

895

Bergisch Gladbach, Bremen, Cologne, Duisburg, Freiburg im Breisgau, Heinsberg, Mettmann, Nuremberg

2018-10-31

Active, closed

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT03703297Small Cell Lung Cancer

DrugsTremelimumab·Durvalumab

AstraZeneca

Phase 3

730

Berlin, Cologne, Freiburg im Breisgau, Gauting, Heidelberg, Mainz, Münster, Oldenburg

2018-09-27

Recruiting

Extension Study for the Port Delivery System With Ranibizumab (Portal)

NCT03683251Neovascular Age-Related Macular Degeneration

DrugPDS Implant with Ranibizumab

Hoffmann-La Roche

Phase 3

1,000

Bonn, Cologne, Cottbus, Freiburg im Breisgau, Hamburg, Ludwigshafen, München, Münster

2018-09-20

Active, closed

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

NCT03948035Newly Diagnosed Multiple Myeloma

DrugsElotuzumab·Carfilzomib·Lenalidomide·Dexamethasone

Wuerzburg University Hospital

Phase 3

576

Freiburg im Breisgau, Mutlangen, Ravensburg, Stuttgart, Ulm, Villingen-Schwenningen, Amberg, Augsburg

2018-08-28

Active, closed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

NCT03398135Ulcerative Colitis (UC)

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,242

Freiburg im Breisgau, Heidelberg, Mannheim, Ulm, Erlangen, Munich, Frankfurt am Main, Kassel

2018-08-28

Active, closed

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

NCT03547973Metastatic Urothelial Cancer

DrugsDomvanalimab·Zimberelimab·Avelumab·Enfortumab Vedotin

Gilead Sciences

Phase 2

502

Duisburg, Frankfurt, Freiburg im Breisgau, Hamburg, Heidelberg, Herne, Jena, Koblenz

2018-08-13

Active, closed

A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

NCT03492177Pulmonary Arterial Hypertension

DrugSelexipag

Actelion

Phase 2

Freiburg im Breisgau

2018-07-23

Active, closed

Thoraflex Hybrid Post-Market Study

NCT03414866Acute Aortic Dissection, Aortic Rupture, Penetrating Aortic Ulcer, Aortic Dissection

Vascutek Ltd.

Observational

182

Freiburg im Breisgau, Hanover

2018-05-25

Active, closed

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT03105102Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,336

Freiburg im Breisgau, Heidelberg, Mannheim, Ulm, Dachau, Erlangen, Regensburg, Frankfurt am Main

2018-04-09

Active, closed

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

NCT03314181Multiple Myeloma

DrugsVenclexta·Bortezomib·Daratumumab·Venetoclax

AbbVie

Phase 2

156

Freiburg im Breisgau, Cologne

2018-04-02

Active, closed

Development of Novel Clinical Endpoints in Intermediate AMD

NCT03349801Age Related Macular Degeneration (AMD)

Frank G. Holz

Observational

718

Bonn, Cologne, Freiburg im Breisgau, Munich, Münster, Tübingen, Ulm

2018-03-26

Active, closed

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

NCT03390504Urothelial Cancer

DrugsVinflunine·Erdafitinib·Docetaxel·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

629

Berlin, Braunschweig, Dresden, Düsseldorf, Erlangen, Frankfurt, Freiburg im Breisgau, Göttingen

2018-03-23

Recruiting

A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.

NCT03320304Treatment Resistant Depression

LivaNova

Observational

500

Bamberg, Bonn, Cologne, Essen, Frankfurt, Freiburg im Breisgau, Göttingen, Hanover

2017-12-14

Active, closed

Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

NCT02799706Prostate Cancer

DrugDegarelix

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

885

Berlin, Freiburg im Breisgau, Magdeburg

2017-09-25

Recruiting

Registry for Patients With X-Linked Hypophosphatemia

NCT03193476X-Linked Hypophosphatemia

Kyowa Kirin Pharmaceutical Development Ltd

Observational

1,489

Bad Belzig, Bochum, Cologne, Dortmund, Freiburg im Breisgau, Hanover, Leipzig, Mainz

2017-09-12

Active, closed

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

NCT03155997Breast Cancer

DrugAbemaciclib

Eli Lilly and Company

Phase 3

5,637

Freiburg im Breisgau, Friedrichshafen, Ludwigsburg, Tübingen, Ulm, Amberg, Augsburg, Erlangen

2017-07-12

Active, closed

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

NCT03164616Non Small Cell Lung Cancer NSCLC

DrugsTremelimumab·Abraxane·Durvalumab·Pemetrexed

AstraZeneca

Phase 3

1,186

Berlin, Essen, Freiburg im Breisgau, Gauting, Hamburg, Heidelberg, Immenhausen, Mainz

2017-06-01

Active, closed

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

NCT03036098Urothelial Cancer

DrugsYervoy·Ipilimumab·Opdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

1,314

Dresden, Essen, Freiburg im Breisgau, Hamburg, Hanover, Jena, Mannheim, Nuremberg

2017-03-24

Recruiting

Neurovascular Product Surveillance Registry

NCT02988128Intracranial Aneurysm, Stroke, Ischemic

Medtronic Neurovascular Clinical Affairs

Observational

4,000

Augsburg, Berlin, Bochum, Erfurt, Erlangen, Essen, Freiburg im Breisgau, Hamburg

2016-12

Active, closed

2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients

NCT02917720Chronic Myeloid Leukemia

DrugNilotinib

European LeukemiaNet

Phase 2

Freiburg im Breisgau, Mannheim, München, Hannover, Aachen, Bayreuth, Chemnitz, Esslingen am Neckar

2016-09

Recruiting

Vercise™ DBS Dystonia Prospective Study

NCT02686125Dystonia

Boston Scientific Corporation

Observational

300

Berlin, Cologne, Düsseldorf, Freiburg im Breisgau, Hamburg, Hamm, Hanover, Kiel

2016-03-07

Active, closed

REDUCER-I: An Observational Study of the Neovasc Reducer™ System

NCT02710435Angina Pectoris, Angina Pectoris, Stable, Chronic Stable Angina

Shockwave Medical, Inc.

Observational

400

Bad Nauheim, Dresden, Essen, Freiburg im Breisgau, Giessen, Hamburg

2016-03

Active, closed

A Study of the ReCor Medical Paradise System in Clinical Hypertension

NCT02649426Hypertension, Vascular Diseases

ReCor Medical, Inc.

Not applicable

282

Düsseldorf, Erlangen, Freiburg im Breisgau, Homburg, Leipzig, Lübeck, Mainz

2016-03

Recruiting

Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care

NCT02638389Vascular Malformations

DrugSirolimus

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 3

250

Freiburg im Breisgau

2016-01-25

Active, closed

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT02598661Myelodysplastic Syndromes

DrugImetelstat Sodium

Geron Corporation

Phase 2/3

289

Freiburg im Breisgau, Dresden, Leipzig, Aschaffenburg, Bonn, Düsseldorf, Mainz

2016-01-12

Active, closed

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

NCT02453282Non-Small-Cell Lung Carcinoma NSCLC

DrugsTremelimumab·Durvalumab·Pemetrexed·Gemcitabine

AstraZeneca

Phase 3

1,118

Aachen, Bad Berka, Berlin, Freiburg im Breisgau, Gauting, Hamburg, Heidelberg, Hemer

2015-07-21

Recruiting

The European NAFLD Registry

NCT04442334NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver

Newcastle University

Observational

10,000

Aachen, Berlin, Freiburg im Breisgau, Mainz, Würzburg

2015-05-01

Active, closed

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

NCT02365597Urothelial Cancer

DrugsErdafitinib·Midazolam·Metformin

Janssen Research & Development, LLC

Phase 2

239

Berlin, Erlangen, Essen, Freiburg im Breisgau, Göttingen, Greifswald, Hamburg, Hanover

2015-04-22

Active, closed

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

NCT02362503HIV Infections

ViiV Healthcare

Phase 3

371

Berlin, Dortmund, Frankfurt, Freiburg im Breisgau, München

2015-02-23

Active, closed

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

NCT02320435Solid Tumors

DrugsPerjeta·Pertuzumab·Trastuzumab

Hoffmann-La Roche

Phase 3

154

Frankfurt am Main, Freiburg im Breisgau, Hamburg, Leer, Neumarkt

2015-02-02

Active, closed

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT02257736Prostatic Neoplasms

DrugsZytiga·Apalutamide·Abiraterone acetate·Prednisone

Aragon Pharmaceuticals, Inc.

Phase 3

982

Berlin, Dresden, Freiburg im Breisgau, Hamburg, Heidelberg, Münster, Nürtingen, Wuppertal

2014-11-26

Active, closed

A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

NCT02130362Crohn's Disease

AbbVie

Observational

1,446

Ulm, Erlangen, Munster, Osnabrück, Aachen, Dresden, Forchheim, Freiburg im Breisgau

2014-08-28

Recruiting

Praegnant Breast Cancer: Early/Advanced/Metastatic

NCT02338167Advanced/Metastatic Breast Cancer, Breast Cancer (Early Breast Cancer)

University Hospital Tuebingen

Observational

13,500

Böblingen, Freiburg im Breisgau, Heidelberg, Karlsruhe, Mannheim, Nürtingen, Tübingen, Ulm

2014-06

Recruiting

The University of Freiburg Medical Center Extracorporeal Organ Support Device Registry

NCT05811780Medical Condition Requiring Extracorporeal Organ Support

University Hospital Freiburg

Observational

1,500

Freiburg im Breisgau

2014-04-29

Active, closed

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

NCT02170090Cholangiocarcinoma, Gall Bladder Carcinoma

DrugsCapecitabine·Gemcitabine·Cisplatin

Universitätsklinikum Hamburg-Eppendorf

Phase 3

789

Hamburg, Aachen, Berlin, Dresden, Essen, Esslingen am Neckar, Frankfurt, Freiburg im Breisgau

2014-04

Recruiting

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

NCT02071134Parkinson's Disease

Boston Scientific Corporation

Observational

1,500

Berlin, Cologne, Düsseldorf, Freiburg im Breisgau, Hamburg, Hamm, Kiel, Mainz

2014-03-04

Active, closed

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT01892722Multiple Sclerosis

DrugsAvonex·Fingolimod

Novartis Pharmaceuticals

Phase 3

240

Freiburg im Breisgau, Göttingen, Dresden, Bochum, Erlangen

2013-07-26

Active, closed

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

NCT01843374Unresectable Pleural or Peritoneal Malignant Mesothelioma

DrugTremelimumab

MedImmune LLC

Phase 2

571

Berlin, Esslingen a.N., Freiburg im Breisgau, Gauting, Großhansdorf, Hamburg, Hemer, Karlsruhe

2013-05-17

Recruiting

German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm)

NCT03125707BCR-ABL1-Negative Myeloid Neoplasms

University of Ulm

Observational

2,172

Augsburg, Bad Saarow, Baden-Baden, Coburg, Donauwörth, Dresden, Erding, Freiburg im Breisgau

2013-05

Active, closed

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

NCT01848561Ulcerative Colitis (UC)

AbbVie

Observational

8,250

Freiburg im Breisgau, Heidelberg, Mannheim, Sigmaringen, Ulm, Erlangen, Memmingen, Munich

2013-04-29

Active, closed

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

NCT01761968Chronic Myeloproliferative Neoplasms

DrugHydroxyurea

Italfarmaco

Phase 2

Berlin, Freiburg im Breisgau

2013-03

Active, closed

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

NCT01357668Juvenile Idiopathic Arthritis

Bristol-Myers Squibb

Observational

800

Bad Bramstedt, Berlin, Freiburg im Breisgau, Hamburg, Heidelberg

2013-01-30

Recruiting

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

NCT01574053Huntington's Disease

CHDI Foundation, Inc.

Observational

35,000

Aachen, Berlin, Bochum, Dresden, Erlangen, Freiburg im Breisgau, Kassel, Lübeck

2012-07

Recruiting

Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood

NCT00662090Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia

University Hospital Freiburg

Observational

260

Freiburg im Breisgau

2010-04

Recruiting

Global Registry and Natural History Study for Mitochondrial Disorders

NCT05554835Mitochondrial Diseases, Kearns-Sayre Syndrome, MIDD, SANDO

LMU Klinikum

Observational

6,000

Munich, Berlin, Bonn, Cologne, Düsseldorf, Frankfurt am Main, Freiburg im Breisgau, Halle

2009-02-01

Recruiting

Effects of Oncological Treatment During Pregnancy on Mother and Child

NCT00330447Cancer, Pregnancy

University Hospital, Gasthuisberg

Observational

5,000

Freiburg im Breisgau

2005-08

Recruiting

Pompe Disease Registry Protocol

NCT00231400Glycogen Storage Disease Type II, Pompe Disease

Genzyme, a Sanofi Company

Observational

2,000

Berlin, Bochum, Bonn, Freiburg im Breisgau, Giessen, Halle, Hamburg, Mainz

2004-09-15

Active, closed

Serial Biomarker Testing and Cardiovascular Risk Stratification (ACHILLES)

NCT07817576Heart Failure, ASCVD, CKD

University Hospital Freiburg

Observational

110,000

Freiburg im Breisgau

2004-01-01

Recruiting

Establishment of a Tumor Bank for Blood Samples

NCT01763125Ovarian Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Neoplasms of the Female Genitalia

Medical University of Vienna

Observational

10,000

Berlin, Freiburg im Breisgau, Herne

2003-11

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 October 2026. https://priyalifescience.com/clinical-trials-germany/city/freiburg-im-breisgau

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,062 studies in total at the last sync on 20 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 391 of those studies with a site in Freiburg im Breisgau.

How many clinical trials are recruiting in Freiburg im Breisgau?

200 of the 391 studies on this page are recruiting new participants as of the 20 Oct 2026, 03:18 UTC sync. A further 14 have not yet opened recruitment, 171 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Freiburg im Breisgau), 391 studies
Phase	Studies	Recruiting	Share
Phase 3	185	81	47.3%
Observational	69	48	17.6%
Phase 2	55	23	14.1%
Not applicable	38	22	9.7%
Phase 1/2	18	12	4.6%
Phase 1	10	4	2.6%
Phase 2/3	9	6	2.3%
Phase 4	7	4	1.8%

Most active sponsors

Lead sponsors with the most studies (Freiburg im Breisgau)
Lead sponsor	Studies	Recruiting
AstraZeneca	37	19
Novartis Pharmaceuticals	24	8
AbbVie	20	5
Hoffmann-La Roche	15	6
Janssen Research & Development, LLC	14	4
University Hospital Freiburg	14	11
Eli Lilly and Company	8	3
Boehringer Ingelheim	7	3
Merck Sharp & Dohme LLC	7	5
Pfizer	6	5

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.